Skip to Content
MilliporeSigma
All Photos(1)

Documents

U0800000

Ursodeoxycholic acid

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

3α,7β-Dihydroxy-5β-cholan-24-oic acid, 5β-Cholan-24-oic acid-3α,7β-diol, 7β-Hydroxylithocholic acid, UDCS

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H40O4
CAS Number:
128-13-2
Molecular Weight:
392.57
Beilstein/REAXYS Number:
3219888
MDL number:
MFCD00003680
UNSPSC Code:
41116107
PubChem Substance ID:
329827593
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

ursodeoxycholic acid

manufacturer/tradename

EDQM

mp

203-204 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1

InChI key

RUDATBOHQWOJDD-UZVSRGJWSA-N

Gene Information

human ... NR1H4(9971)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ursodeoxycholic acid EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H315,H319

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 7

1 of 7

Deoxycholic Acid (Desoxycholic Acid) United States Pharmacopeia (USP) Reference Standard

USP

1171273

Deoxycholic Acid (Desoxycholic Acid)

Taurolithocholic acid 3-sulfate disodium salt

Sigma-Aldrich

T0512

Taurolithocholic acid 3-sulfate disodium salt

Tauroursodeoxycholic Acid, Sodium Salt Tauroursodeoxycholic is a detergent useful for the solubilization of lipids and membrane-bound proteins.

Millipore

580549

Tauroursodeoxycholic Acid, Sodium Salt

Chenodeoxycholic acid

Sigma-Aldrich

C9377

Chenodeoxycholic acid

Lithocholic acid ≥95%

Sigma-Aldrich

L6250

Lithocholic acid

Cholic acid from bovine and/or ovine, ≥98%

Sigma-Aldrich

C1129

Cholic acid

Deoxycholic acid ≥98% (HPLC)

Sigma-Aldrich

D2510

Deoxycholic acid

Marco Carbone et al.
Gastroenterology, 144(3), 560-569 (2012-12-19)
BACKGROUND, & AIMS: Studies of primary biliary cirrhosis (PBC) phenotypes largely have been performed using small and selected populations. Study size has precluded investigation of important disease subgroups, such as men and young patients. We used a national patient cohort
Li-Na Zhang et al.
Hepatology (Baltimore, Md.), 58(1), 264-272 (2013-02-15)
The biochemical response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis is a strong predictor of long-term outcome and thus facilitates the rapid identification of patients needing new therapeutic approaches. Numerous criteria for predicting outcome of treatment have been studied
R A Rubin et al.
Annals of internal medicine, 121(3), 207-218 (1994-08-01)
To explain the rationale supporting the use of ursodiol (ursodeoxycholic acid) for the treatment of patients with cholesterol gallstones and chronic liver diseases and to describe the results obtained in clinical trials. Personal databases of the authors and MEDLINE were
Ursodeoxycholic acid for the treatment of primary biliary cirrhosis.
Keith Lindor
The New England journal of medicine, 357(15), 1524-1529 (2007-10-12)
Ursodeoxycholic acid in chronic hepatitis C.
Raoul Poupon et al.
Gut, 56(12), 1652-1653 (2007-11-14)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service